Side effects of pharmaceuticals not elicited by comparable herbal medicines: The case of tetrahydrocannabinol and marijuana

Alternative Therapies in Health and Medicine

Volumn 5, Issue 4, 1999, Pages 57-62

  McPartland, J M ^a   Pruitt, Patty L ^b  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^b Alternative Med Res Inst T   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; CANNABIS; TETRAHYDROCANNABINOL;

COMPARATIVE STUDY; HUMAN; MEDICINAL PLANT; REVIEW;

ANALGESICS, NON-NARCOTIC; CANNABIS; HUMANS; PLANTS, MEDICINAL; TETRAHYDROCANNABINOL;

EID: 0033160865     PISSN: 10786791     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (101)

1. Duke J. The synthetic silver bullet vs the herbal shotgun shell. HerbalGram. 1989;18,19:12-13.
2. McPartland JM. Treating benign prostatic hyperplasia with saw palmetto: a literature review and an N=1 clinical trial. J Am Osteopath Assoc. 1999. In press.
3. McPartland JM. Viral hepatitis treated with Phyllanthus amarus and milk thistle (Silybum marianum): a case report. Complement Med Int. 1996;3(2):40-42.
4. Bauer R, Wagner H. Echinacea species as potential immunostimulatory drugs. Econ Med Plant Res. 1991;5:253-321.
5. McPartland JM, Mitchell J. Caffeine and chronic back pain. Arch Phys Med Rehabil. 1997;78(1):61-63.
6. Bisset NG, ed. Herbal Drugs and Plytopharmaceuticals: A Handbook for Practice on a Scientific Basis. Boca Raton, Fla: CRC Press; 1994.
7. Racz-Kotilla E, Racz G, Solomon A. The action of Taraxacum officinale extracts on the body weight and diuresis of laboratory animals. Planta Med. 1974;26(3):212-217.
8. Grases F, Melera G, Costa-Bauzá A, Prieto R, March JG. Urolithiasis and phytotherapy. Int Urol Nephrol. 1994;26:507-511.
9. Joy JE, Watson SJ, Benson JA, eds. Marijuana and Medicine: Assessing the Science Base. Washington. DC: National Academy Press; 1999.
10. Grinspoon L, Bakalar JB. Marihuana: The Forbidden Medicine. Revised ed. New Haven, Conn: Yale University Press; 1997.
11. McPartland JM, Pruitt PL. Medical marijuana and its use by the immunocompromised. Altern Ther Health Med. 1997;3(3):39-15.
12. Isbell H, Gorodetzsky GV, Jasinski D, Claussen U, Spulak F, Korte F. Effects of (-) delta-9-tetrahydrocannabinol in man. Pychopharmacologia. 1967;11:184-188.
13. Cocchetto DM, Cook LF, Cato AE. A critical review of the safety and antiemetic efficacy of delta-9-tetrahydrocannabinol. Drug Intell Clin Pharm. 1981;15:867-875.
14. Perez-Reyes M, Wall ME. The metabolism of delta-9-tetrahydrocannabinol and related cannabinoids in man. J Clin Pharmacol. 1981;21:178S-189S.
15. Browne RG, Weissman A. Discriminative stimulus properties of delta 9-tetrahydro-cannabinol: mechanistic studies. J Clin Pharmacol. 1981;21(suppl 8-9):227S-234S.
16. Ohlsson A, Lindgren JE, Wahlen A, Agurell S, Hollister LE, Gillespie HK. Plasma delta-9-tetrahydrocannabinol concentrations and clinical effects after oral and intravenous administration and smoking. Clin Pharmacol Ther. 1980;28:409-416.
17. Schwartz RH, Voth EA. Marijuana as medicine: making a silk purse out of a sow's ear. J Addict Dis. 1995;14:15-21.
18. Tashkin DP, Reiss S, Shapiro BJ, Calvarese B, Olsen JL, Lodge JW. Bronchial effects of aerosolized delta-9-tetrahydrocannabinol in healthy and asthmatic subjects. Am Rev Respir Dis. 1977;115:57-65.
19. Bouaboula M, Rinaldi M, Carrayon P, et al. Cannabinoid-receptor expression in human leukocytes. Eur J Biochem. 1993;214:173-180.
20. Nahas GG, Suciu-Foca N, Armand JP, Hsu J, Morishima A. Inhibition of cellular mediated immunity in marijuana smokers. Science. 1974;183:419-420.
21. White SC, Brin SC, Janicki BW. Mitogen-induced blastogenic responses of lymphocytes from marijuana smokers. Science. 1975;188:71-72.
22. Lau RJ, Tubergen DG, Barr M, Domino EF, Benowitz N, Jones RT. Phytohemagglutinininduced lymphocyte transformation in humans receiving delta-9-tetrahydrocannabinol. Science. 1976;192:805-807.
23. Rachelfsky GS, Opedz G. Normal lymphocyte function in the presence of delta-9-THC. Clin Pharmacol Ther. 1977;21:44-46.
24. Klein TW, Friedman H, Specter S. Marijuana, immunity and infection. J Neuroimmunol. 1998;83:102-115.
25. Miller LL, Branconnier RJ. Cannabis: effects on memory and the cholinergic limbic system. Psychol Bull. 1983;93:441-456.
26. Gifford AN, Samiian L. Galley SJ, Ashby CR Jr. Examination of the effect of the cannabinoid receptor agonist, CP 55,940, on electrically evoked transmitter release from rat brain slices. Eur J Pharmacol. 1997;324:187-192.
27. Hampson AJ, Bornheim LM, Scanziani M, et al. Dual effects of anadamide on NMDA receptor-mediated responses and neurotransmission. J Neurochem. 1998;70:671-676.
28. Maneuf YP, Nash JE, Crossman AR, Brotchie JM. Activation of the cannabinoid receptor by delta 9-tetrahydrocannabinol reduces gamma-aminobutyric acid uptake in the globus pallidus. Eur J Pharmacol. 1996;308:161-164.
29. Poddar MK, Dewey WL. Effects of cannabinoids on catecholamine uptake and release in hypothalamic and striatal synaptosomes. J Pharmacol Exp Ther. 1980;214:63-67.
30. Gardner EL, Lowinson JH. Marijuana's interaction with brain reward systems: update 1991. Pharmacol Biochem Behav. 1991;40:571-580.
31. French ED, Dillon K, Wu X. Cannabinoids excite dopamine neurons in the ventral tegmentum and substantia nigra. Neuroreport. 1997;8:649-652.
32. 1 opioid receptor mechanism. Science. 1997;276:2048-2050.
33. Nahas GG. Marihuana: Deceptive Weed. New York, NY: Raven Press; 1972.
34. Nahas GG, Latour C. The human toxicity of marijuana. Med J Aust. 1992;156:495-497.
35. Liskow BI, reviewer. JAMA. 1973:224:631. Review of: Nahas GG. Marihuana: Deceptive Weed.
36. Liskow BI, reviewer. JAMA. 1973:224:631. Review of: Nahas GG. Marihuana: Deceptive Weed.
37. Consroe P. The human toxicity of marijuana. Med J Aust. 1995;162:54.
38. Christie MJ, Chesher GB. The human toxicity of marijuana: a critique of a review by N'ahas and Latour. Drug Alcohol Rev. 1994;13:209-216.
39. Turner CE, Elsohly MA, Boeren EG. Constituents of Cannabis saliva L. XVII. A review of the natural constituents. J Nat Prod. 1980;43:169-304.
40. Thompson GR, Rosenkrantz H, Schaeppi UH, Braude MC. Comparison of acute oral toxicity of cannabinoids in rats, dogs and monkeys. Toxicol Appl Pharmacol. 1973;25:363-373.
41. Carlini EA, Cunha JM. Hypnotic and antiepileptic effects of cannabidiol. J Clin Pharmacol. 1981;21:4175-4275.
42. Zuardi AW, Shirakawa I, Finkelfarb E, Kamiol IG. Action of cannabidiol on the anxiety and other effects produced by delta-9-THC in normal subjects. Psychopharmacology. 1982;76:245-250.
43. Kamiol IG, Shirakawa I, Kasinski N, Ffeferman A, Carlini EA. Cannabidiol interferes with the effects of delta-9-tetrahydrocannabinol in man. Eur J Pharmacol 1974;28:172-177.
44. Zuardi AE, Antunes Rodrigues J, Cunha JM. Effects of cannabidiol in animal models predictive of antipsychotic activity. Pychopharmacology. 1991;104:260-264.
45. Zuardi AW, Morais SL, Guimarães FS, Mechoulam R. Antipsychotic effect of cannabidiol. J Clin Psychiatry. 1995;56:485-486.
46. Petitet F, Jeantaud B, Imperato A, Dubroeucq MC. Complex pharmacology of natural cannabinoids: evidence for partial agonist activity of delta-9-tetrahydrocannabinol and antagonist activity of cannabidiol on rat brain cannabinoid receptors. Life Sci. 1998;63:PL1-6.
47. Onaivi ES, Akinshola BE, Chakrabarti A. Cannabinoid (CB1) Receptor Antagonism Induces Anxiolysis. Burlington, Vt: International Cannabinoid Research Society; 1998:132.
48. Bornheim LM, Kim KY, Li J, Perotti BY, Benet LZ. Effect of cannabidiol pretreatment on the kinetics of tetrahydrocannabinol metabolites in mouse brain. Drug Metab Dispos. 1995;23:825-831.
49. He K, Iyer KR, Hayes RN, Sinz MW, Woolf TF, Hollenberg PF. Inactivation of cytochrome P450 3A4 by bergamottin, a component of grapefruit juice. Chem Res Toxicol. 1998;11:252-259.
50. Ross SA, Elsohly MA. The volatile oil composition of fresh and air-dried buds of Cannabis sativa. J Kat Prod. 1996;59:49-51.
51. Mediavilla V, Steinemann S. Essential oil of Cannabis saliva L strains. J Int Hemp Assoc. 1997;4:82-84.
52. Buchbauer G, Jirovetz L, Jäger W, Plank C, Dietrich II. Fragrance compounds and essential oils with sedative effects upon inhalation. J Pharm Sci. 1993;82:660-664.
53. Brown H. Some anticholinergic-like behavioural effects of trans (-)-delta-8 tetrahydrocannabinol. Psychopharmacologla. 1971:21:294-301.
54. Grundy DL, Still CC. Inhibition of acetylcholinesterases by pulegone-1, 2-epoxide. Pcslic Biochcm Physiol. 1985:23:383-388.
55. Gracza L. Biochemisch-pharmakologische Untersuchung pflanzlicher Arzneistoffe, II. Hemmung der Acetylcholinesterase durch Monoterpenderivate in vitro. ZXaturforsch [C]. 1985:40:151-153.
56. Perry N, Court G, Bidet N, Court J, Perry E. European herbs with cholinergic activity: potential in dementia therapy. Int J Geriatr Psychiatry. 1996:11:1063-1069.
57. Miyazawa M, Watanabe H, Kameoka H. Inhibition of acetylcholinesterase activity by monoterpenoids with a p-methane skeleton.J Agric Food Chem. 1997:45:677-679.
58. Domino EF. Effect of delta-9-tetrahydrocannabinol and cannabinol on rat brain acetyl-choline. In: Nahas GG, Panton WDM, Idanpaan-Heikkila JE, eds. Marijuana: Chemistry, Biochemistry, and Cellular Effects. New York, NY: Springer-Verlag; 1976:407-413.
59. Cheney DL, Revuelta AV, Costa E. Marijuana and cholinergic dynamics. In: Pepeu G, Ladinsky H, eds. Cholinergic Mechanisms: Phyhgcnctic Aspects, Central and Peripheral Synapses, and Clinical Significance. New York, NY: Plenum Press; 1981.
60. Heyser CJ, Hampson RE, Deadwyler SA. Effects of delta-9-tetrahydrocannabinol on delayed match to sample performance in rats: alterations in short-term memory asso-ciated with changes in task specific firing of hippocampal cells.J Pharmacol Exp Ther. 1993:264:294-307.
61. Brodkin J, Moerschbaecher JM. SR141716A antagonizes the disruptive effects of cannabinoid ligands on learning in rats.J Pharmacol Exp Ther. 1997:282:1526-1532.
62. Volicer L Dronabinol may help behavior problems in Alzheimer's disease. Am Fam Pract. 1997:55:1338.
63. Hampson AJ, Grimaldi M, Wink D. Cannabidiol and (-)delta-9-tetrahydrocannabinol are neuroprotective antioxidants. Proc KatlAcadSci USA. 1998;s95:8268-8273.
64. Banerjee SP, Snyder SI I, Mechoulam R. Cannabinoids: influence on neurotransmitter uptake in rat brain synaptosomes.J Pharmacol Exp Ther. 1975:194:74-81.
65. Nasel C, Nasel B, Samec P, Schindler E, Buchbauer G. Functional imaging of effects of fragrances on the human brain after prolonged inhalation. Chem Senses. 1994;19:359-364.
66. Mathew RJ, Wilson WH. Acute changes in cerebral blood flow after smoking marijuana. Life Sci. 1993:52:757-767.
67. Schultz OE, Haffher G. Zur Kenntnis eines sedativen und antibakteriellen \Virkstoffes aus dem deutschen Faserhanf (Cannabis saliva). Z Naturforsch B. 1959;14:98-100.
68. Klingeren BV, Ham MT. Antibacterial activity of delta-9-tetrahydrocannabinoI and cannabidiol.Antonie Van Leeuwenhock. 1976;42:9-12.
69. McPartland JM. Pathogcnicity of Phomopsis ganjae on Qnnabis saliva and the fùngislat-ic effect of cannabinoids produced by the host. Mycopalliologla. 1984:87:149-153.
70. Elsohly HN, Turner CE, Clark AM. Elsohly MA. Synthesis and antimicrobial activities of certain cannabichromene and cannabigerol related compounds.J Pharm Sci. 1982:71:1319-1323.
71. Turner CE, Elsohly MA. Biological activity of cannabichromene, its homologs and iso-mers.J Clin Pharmacol. 1981;21:283S-291S.
72. Gal IE, Vajda O, Bekes I. A kannabidiolsav nehany tulajdonsâgânak vizsgâlata élelmisz-ertartôsïtâsi szempontbôl. Eklmiszemxgalali Kfàcmmyck. 1969:4:208-216.
73. Farkas J, Andrâssy É. The sporostatic effect of cannabidiolic acid. Ada Alimailaria. 1976:5:57-67.
74. Fournier G, Paris MR, Fourniat MC, Quero AM. Activité bactériostatique d'huiles essentielles de Cannabis saliva L. Ann Pharm Fr. 1978:36:603-605.
75. Kubo I, Muroi H, Himejima M. Antimicrobial activity of green tea flavor components and their combination effects.J Agric Food Chem. 1992;40:245-248.
76. Kang R, Helms R, Stout MJ, Chen Z, Nakatsu T. Antimicrobial activity of the volatile constituents of Perilla frutescens and its synergistic effects with polygodial.J Agric Food Chem. 1992:40:2328-2330.
77. Dean SG. Evaluation of antimicrobial activity of essential (volatile) oils. In: Linskens HF, Jackson JF, eds. Essential Oils and Waxes. Berlin, Germany: Springer-Verlag; 1991:309-320.
78. Wilson CL, EIGhaouth A, Wisniewski ME. Rapid evaluation of plant extracts and essen-tial oils for antifungal activity against Botrytis cinerea. Plant Dis. 1997:81:204-210.
79. Kurita N, Miyaji M. Kurane R, Takahara Y. Antifungal activity of components of essen-tial oils. Agric Biol Chem. 1981:45:945-952.
80. Che CT. Plants as a source of potential antiviral agents. Econ Med Plant Res. 1991:5:167-251.
81. Maruzzella JC, Sicurella NA. Antibacterial activity of essential oil vapors.J Am Pharm Assoc. 1960:42:692-694.
82. Paster N, Menasherov N, Ravid U, Juven B. Antifungal activity of oregano and thyme essential oils applied as fumigants against fungi attacking stored grain. J Food Protection. 1990:58:81-85.
83. Burstein S, Levin E, Varanelli C. Prostaglandins and Cannabis. 2. Inhibition of biosyn-thesis by the naturally occurring cannabinoids. Biochcm Pharmacol. 1973:22:2905-2910.
84. Evans FJ. Cannabinoids: the separation of central from peripheral effects on a structur-al basis. Planta Med. 1991;57(suppl 1):S60-S67.
85. Formukong EA, Evans AT, Evans FJ. Analgesic and anti-inflammatory activity of con-stituents of Cannabis saliva L Inflammation. 1988:12:361-371.
86. Barrett ML, Scutt AM, Evans FJ. Cannaflavin A and B, prenylated flavones from Cannabis saliva L. Experientia. 1986:42:452-453.
87. Clarke MN, Bohm BA. Flavonoid variation in Cannabis L. Bot J Linnean Soc. 1979:79:249-257.
88. Gerritsen ME, Carley WW, Ranges GE, et al. Flavonoids inhibit cytokine-induced endothelial cell adhesion prolein gene expression. Am J Pathol. 1995:147:278-292.
89. Sauer MA, Rifka SM, Hawks RL, Culler GB, Loriaux DL. Marijuana: infraction with the estrogen nteploc.J Pharmacol Exp Ther. 1983:224:404-407.
90. Burslein S, Varanelli C, Slade LT. Prostaglandins and Cannabis. 3. Inhibition of biosyn-lhesis by essenlial oil components of marihuana. Biochcm Pharmacol. 1975:24:1053-1054.
91. Burstein S, Taylor P, El-Feraly FS, Turner C. Prostaglandins and Cannabis. 5. Identification of p-vinylphenol as a polent inhibitor of prostaglandin synlhesis. Biochem Pharmacol. 1976:25:2003-2004.
92. Evans AT, Formukong EA, Evans FJ. Actions of cannabis conslituenls on enyzmes of arachidonate metabolism: anli-inflammatory potenlial. Biochem Pharmacol. 1987:36:2035-2037.
93. Wang C, Kurzer MS. Effects of phyloeslrogens on DNA synthesis in MCF-7 cells in the presence of estradiol or growth factors. Nutr Cancer. 1998:31:90-100.
94. Chait LD, Pierri J. Some physical characterislics of NIDA marijuana cigarelles. Addict Behav. 1989:14:61-67.
95. Sparacino CM, Hyldburg PA, Hughes TJ. Chemical and biological analysis of marijua-na smoke condensale. NIDA Res Monogr. 1990:99:121-140.
96. Voth EA. Marijuana and its reviews. N Engl J Med. 1995:332:274.
97. Huber GJ, First MW, Grubner O. Marijuana and tobacco smoke gas-phase cytotoxins. Pharmacol Biochem Behav. 1991:40:629-636.
98. Gieringer D. Marijuana research: waterpipe study. MAPS (Multidisciplinary Assoc Psychedelic Stud) Bull. 1996;6(3):59-66.
99. Slix G. Herb remedy: exploring ways Io administer marijuana as a medicine. Sci Am. 1998;279(3):18-19.
100. Gorter RW. Schnelle M, Stoss M, van Wely M. Cannabis in der Behandlung Kreb-skranker und HIV-positiver patienten die erste klinische Cannabis-studie in Deulschland. In: Proceedings of the Bioresource Hemp Symposium. Hürth, Germany: Nova Institute; 1997:691-692.
101. Graham JDP. If Cannabis were a new drug. In: Graham JDP, éd. Cannabis and Health. London, England: Academic Press; 1976:417-437.